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Tumor environment can be critical for preventing the immunological destruction of 
antigenic tumors. We have observed a selective accumulation of CD4
 
 
 
CD25
 
 
 
 T cells inside 
tumors. In a murine fibrosarcoma L
 
d
 
-expressing Ag104, these cells made up the majority 
of tumor-infiltrating lymphocytes at the late stage of tumor progression, and their 
depletion during the effector phase, rather than priming phase, successfully enhanced 
antitumor immunity. We show here that CD4
 
 
 
CD25
 
 
 
 T cells suppressed the proliferation 
and interferon-
 
 
 
 production of CD8
 
 
 
 T cells in vivo at the local tumor site. Blockade of 
the effects of IL-10 and TGF-
 
 
 
 partially reversed the suppression imposed by the CD4
 
 
 
 cells. 
Furthermore, local depletion of CD4
 
 
 
 cells inside the tumor resulted in a change of cytokine 
milieu and led to the eradication of well-established highly aggressive tumors and the 
development of long-term antitumor memory. Therefore, CD4
 
 
 
CD25
 
 
 
 T cells maintained 
an environment in the tumor that concealed the immunogenicity of tumor cells to permit 
progressive growth of antigenic tumors. Our study illustrates that the suppression of 
antitumor immunity by regulatory T cells occurs predominantly at the tumor site, and that 
local reversal of suppression, even at a late stage of tumor development, can be an effective 
treatment for well-established cancers.
 
Cancers often progress in immunocompetent
hosts and are defined as having poor immuno-
genicity (1–4). It was thought that the failure
to elicit an immune response was due to the
lack of recognizable antigens. However, it is
now evident that, in mice and humans, tumor
cells can be antigenic due to encoded genes
that are either normal, but aberrantly or over-
expressed, or altered as the result of cancer-
specific somatic mutations (3, 5–15). Although
most of the tumor antigen-specific lymphocytes
that recognize self antigens would normally be
subjected to self tolerance processes (16, 17),
lymphocytes recognizing mutated antigens,
which are absolutely specific for the tumor
cells, should not have undergone the same
regulatory processes that accompany self toler-
ance (18). The notion that immune recognition
of cancer occurs frequently, if not universally,
in cancer patients, is consistent with the fre-
quent observation of T cell infiltration into can-
cer tissues (19–22). However, it is exceptional
for such tumor-infiltrating T cells to induce the
spontaneous rejection of the established tumors.
This curious paradox of antigenic and immune-
recognized tumor cells that fail to elicit its
rejection in immune competent hosts remains
largely inexplicable.
Many studies present the possibility of a
local environment at the tumor site may play
critical roles for preventing the immunological
destruction of antigenic tumors. One of the
best examples is concomitant tumor immu-
nity, a phenomenon observed in both animals
and humans, in which tumor-bearing hosts fail
to reject their primary tumor but generate sys-
temic immunity to resist subsequent tumor
implants of the same tumor cells at secondary
sites (23). Even when the host bears a poorly
immunogenic cancer, concomitant immunity
can be rescued by systemic depletion of the
CD4
 
 
 
CD25
 
 
 
 regulatory T cell subset (24).
In other studies, mice that were incapable of
rejecting established malignant tumor grafts
were able to reject nonmalignant grafts that
expressed the same strong, recognizable anti-
gens (1, 25). The tumor antigen-specific T cells
in these tumor-bearing hosts that failed to
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Figure 1. CD4 CD25  T cells accumulate inside the tumor to suppress 
tumor rejection. (a) A strong antigen Ld does not hinder tumor growth. 
5   105 Ag104 and Ag104Ld tumor cells were inoculated to C3B6F1 mice s.c. 
Tumor growth was monitored and volume was calculated as follows: vol-
ume   length   width   height/2. Three individual experiments ( 3 mice 
per group) were pooled and shown. (b–e) 106 Ag104Ld tumor cells were inocu-
lated to C3B6F1 mice s.c. at tail base and inguinal LN, spleen, and tumor tissue 
were isolated from the mice 7 or 16 d after tumor challenge. The percentage 
of CD4 CD25  T cells among lymphocytes (b) and the expression of CD45RB 
on CD4 CD25  or CD4 CD25  T cells (c) were determined by FACS. Results 
from pooled three experiments with three mice examined at each time point 
were shown. Spleen and tumor tissue were collected from these tumor-
bearing mice 16 d after tumor challenge. CD4  T cells were enriched from the 
spleen with a negative selective bead method using magnetic system. 
CD4 CD25  T cells from the spleen were further separated from CD4 CD25  
T cells with magnetic system. Tumor-infiltrating T cells were enriched with 
biotinylated anti-Thy1.2 antibody followed by antibiotin magnetic beads. 
CD4  T cells infiltrating the tumor were further isolated with FACS sorting 
after stained with PE conjugated anti-CD4 antibody. (d) Total RNA was iso-
lated from these purified CD4  T cell populations and real-time RT-PCR for 
foxp3 was done on cDNA derived from the RNA. (e) 5   104 per well in a 96-
well plate purified CD4 CD25  T cells from naive mice were stimulated with 
optimal dose (2  g/ml) of coated anti-CD3 antibody for 72 h. Or 5   104 
CD4  T cells from tumor tissue or spleen of tumor-bearing mice were added 
to coculture with purified CD4 CD25  T cells and 3H was added for the last 
24 h of culture and its incorporation was measured. Data shown were means 
and SD. (f) Anti-CD25 antibody was given to mice 14 d after tumor challenge, 
spleen and tumor tissues were collected 2 d later and the percentage of 
CD25  or CD25  cells among CD4 or CD8 cells were compared with the one 
with control treatment. The representative data from one out of three experi-
ments was shown. Tumor growth was monitored when CD4  (g) or CD25  
(h) cells were depleted with antibody in vivo. The tumor growth pattern in one 
experiment representative of seven independent experiments with three to 
five mice in each group, either CD4-depleted or control group was shown in 
g. (h) Tumor volume at each time point was measured on 12 mice in each 
group, either CD25-depleted or control group, done in four independent ex-
periments and data shown were means and SD. The difference in tumor 
growth between the two groups was significant (P   0.001, the random 
effect models for longitudinal data). Tumor sizes were also significantly differ-
ent between two groups after 20 d after tumor inoculation (P   0.001, t test). 
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mediate rejection of the established tumor were neither
clonally exhausted, nor systemically anergized, nor ignorant
(1). Finally, the defect in TCR signal-transducing molecules
in cancer patients was found to be much more pronounced
in T cells infiltrating the tumor than the ones in the periph-
eral blood (26). All of these studies imply that a growing tu-
mor harbors the ability to induce an antigen-specific de-
structive immune response while suppressing the effects of
this immunity at the site of the established tumor. Stromal
barrier inside the tumor has been proposed to be one of the
important local factors to hinder T cell access to the estab-
lished malignant tissues (1, 27, 28). However, other mecha-
nisms may contribute to local suppression in the presence of
infiltrating lymphocytes.
The CD4
 
 
 
CD25
 
 
 
 T cell subset (29, 30) has been estab-
lished to be a powerful regulator of T cell responses in or-
gan-specific autoimmunity and chronic infections (31–35).
Earlier studies by Robert North and his colleagues have
shown that cell-mediated suppression of antitumor immu-
nity led to the progressive growth of an immunogenic tumor
(36). The tumor-induced suppressor cells expressed the
CD4
 
 
 
CD8
 
 
 
 surface phenotype (37), and intravenous injec-
tion of a depleting anti-CD4 antibody led to CD8
 
 
 
 T cell–
mediated tumor regression (38). The antibody was given at
early stages of tumor growth and ineffective if T cell help
was required to generate an immune response to the tumor.
A major advance resulted from the discovery that the sup-
pressive CD4
 
 
 
 T cell subset could be separated from CD4
 
 
 
helper T cells by the expression of high levels of CD25 (29,
30) and that this subset had important regulatory functions in
preventing autoimmunity to self antigens (31, 33–35). Im-
portantly, it was also shown that elimination of these regula-
tory T cells, despite causing increased autoreactivity, could
increase immune responses to tumors such as melanomas
overexpressing self-antigens as targets (39–42). Here, we
have found that CD4
 
 
 
CD25
 
 
 
 T cells selectively accumu-
lated inside the tumor. These cells maintained a local cyto-
kine environment that suppressed the effector function of tu-
mor-infiltrating CD8
 
 
 
 T cells at the tumor site. Intratumoral
depletion of these CD4
 
 
 
CD25
 
 
 
 T cells unmasked the im-
munogenicity of the tumors and reversed CTL tolerization
leading to rapid rejection of well-established tumors. There-
fore, we have revealed an important mechanism in the tu-
mor environment that prevents immune destruction of the
antigenic cancer. Our study shows that CD4
 
 
 
CD25
 
 
 
 T cells
exert their suppressive effects predominantly in the tumor
and abrogating their effects at the tumor site can be a highly
efficient approach to enhance antitumor immunity.
 
RESULTS
A strong antigen does not hinder tumor growth
 
Human cancers are often antigenic, and it is puzzling why
most human cancers fail to induce their rejection, even when
there is significant infiltration of lymphocytes into the tumor
Figure 1 (continued) 
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tissues (3, 14). In an attempt to further analyze what types of
T lymphocytes infiltrate the tumor tissues, we found interest-
ingly that very few CD4
 
 
 
 T cells infiltrated the breast cancer
tissues we examined during the early stages of tumor progres-
sion. However, as the tumors progressed, the CD4
 
 
 
 T cell
population increased dramatically inside the tumor (unpub-
lished data). Because of the limitations in exploring the essen-
tial roles of these tumor-infiltrating CD4
 
 
 
 T cells for tumor
progression in vivo with human cancers, we developed a mu-
rine tumor model that closely resembles human cancers with
some infiltration of both CD4
 
 
 
 and CD8
 
 
 
 T cells. Ag104, a
poorly differentiated solid tumor that arose spontaneously in
C3H mouse, is highly progressive, poorly immunogenic, and
resistant to immunotherapy (27, 43, 44). Ag104 cancer cells
regularly cause tumors in both C3H and C3HXB6F1
(C3B6F1) mice when as few as 10
 
4
 
 cells are inoculated. The
low immunogenicity of this tumor, which leads to rapid
growth in immunocompetent syngeneic wild-type mice in
vivo, could be due to either a lack of or weak expression of
tumor antigens. In an attempt to rule out this caveat, we
transfected Ag104 tumor cell line with a gene encoding the
L
 
d
 
 antigen, a strong antigen. The transfected tumor cell line
expressed high levels of L
 
d
 
 in vitro. Unexpectedly, the L
 
d
 
-
expressing Ag104 (Ag104L
 
d
 
) tumor grew with similar kinetics
to the parental tumor at the dose of as low as 10
 
4
 
. The tumor
growth resulting from subcutaneous inoculation of 5 
 
 
 
 10
 
5
 
tumor cells into C3B6F1 mice in three experiments is shown
in Fig.1 a. It has been reported that antigen-lost variant could
be selected to avoid immune recognition (4, 45, 46). How-
ever, we found that Ag104L
 
d
 
 tumor cells isolated from the
tumor-bearing mice expressed comparable level of L
 
d
 
 as the
cells before injection (unpublished data). We concluded from
this experiment that antigenic tumors can progress without
losing their tumor antigens. Thus, it is unlikely that the poor
immunogenicity of the Ag104L
 
d
 
 tumor, indicated by their
rapid growth in immunocompetent syngeneic wild-type
mice in vivo, was caused by low expression of MHC class I
or by the loss of antigen.
One reason why antigen L
 
d
 
 did not hinder tumor growth
could be that this antigen was ignored and never seen by the
immune system. To test this possibility, we surgically re-
moved the Ag104L
 
d
 
 tumor 21 d after its inoculation and
then rechallenged the mice with a larger dose of tumor cells
4 wk after the surgery. Surprisingly, all these mice rejected
the second tumor challenge, although the naive mice died of
the tumor burden (Table I). This result indicated that the T
cells were primed to the L
 
d
 
 antigen and after the surgical re-
moval of the tumor, these T cells were able to evolve into
memory cells and confer protection against the second tu-
mor challenge. We were able to show that these memory T
cells were predominately L
 
d
 
-specific because these mice
could not reject the parental tumor Ag104 (Table I). These
results suggested to us that antigen-specific T cells do exist,
but do not function properly in the tumor-bearing animals.
It raises a possibility that poor immunogenicity of Ag104L
 
d
 
tumor may not be attributed to poor immune recognition
but to aberrant immune responses in the presence of tumor,
particularly within the tumor microenvironment.
 
CD4
 
 
 
CD25
 
 
 
 T cells accumulate inside the tumor
 
To investigate the cause of impaired tumor rejection even in
the presence of immunogenic antigens, we first examined
the tumor-infiltrating lymphocytes (TIL) in our animal
model. Immunohistochemical and FACS stainings revealed
that the Ag104L
 
d
 
 tumor tissues were infiltrated with both
CD4
 
 
 
 and CD8
 
 
 
 cells that were colocalized. Very few tu-
mor-infiltrating DX5
 
 
 
 NK or NK T cells were observed
(unpublished data). Surprisingly, the lymphocytes that accu-
mulated in the tumor mainly consisted of the CD4
 
 
 
CD25
 
 
 
T cell subset (Fig. 1 b). We then compared the percentage of
the CD4
 
 
 
CD25
 
 
 
 T cells among lymphocytes in the spleen,
the draining lymph nodes (DLN), and the tumor on 0, 7, or
16 d after tumor challenge. We found that, with time, the
percentage of the CD4
 
 
 
CD25
 
 
 
 T cells increased dramati-
cally inside tumor although it remained constant in the
spleen and DLN (Fig. 1 b). These data indicated that an in-
 
Table I.
 
CD4 depletion induces immune responses against antigens other than Ld
 
First tumor challenge
 
a
 
Rechallenge
 
a
 
Group Tumor line Dose Treatment Tumor line Dose
Incidence of tumor 
growth
 
b
 
Percent
 
1 Ag104Ld 5 
 
  
 
10
 
5 Surgical removalc Ag104Ld 106 0/3 0
25     105 Ag104 106 3/3 100
35     105 CD4 depletiond Ag104Ld 106 0/10 0
45     105 Ag104 106 0/7 0
5 None None Ag104Ld 106 33/33 100
6 Ag104 106 20/20 100
aNumber of tumor cells as indicated were injected s.c. to C3B6F1 mice. Rechallenge was done 30 d after first tumor was surgically removed or rejected upon anti-CD4 antibody 
treatment.
bThe results were pooled from independent experiments. p-values calculated by chi-square test between groups were shown as follows: P   0.001 for group 1 versus group 5, 
group 3 versus group 6, and group 4 versus group 6. P   0.5 for group 2 versus group 5.
cThe tumors were surgically removed 21 d after first tumor challenge.
dCD4  cells were depleted by anti-CD4 antibody 14 d after first tumor challenge. Depletion was confirmed by checking peripheral blood with FACS.JEM VOL. 201, March 7, 2005 783
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creased percentage of CD4 CD25  T cells was present at
the effector site, but not in the lymphoid organs. These
CD4 CD25  T cells were of CD45RBlow phenotype (Fig. 1
c), which is consistent with what had been observed on
CD4 CD25  regulatory T cells (35). FOXP3 is a forkhead/
winged helix transcription factor critical for mouse CD4 
CD25  regulatory T cell differentiation and function
(47–49). The real-time quantitative RT-PCR demonstrated
much stronger expression of foxp3 mRNA in CD4  T cells
isolated from the tumor in comparison with CD4  T cells
isolated from the spleen of the tumor-bearing animals or
CD4 CD25  T cells from the spleen of naive mice (Fig. 1
d). These observations raise the possibility that the CD4 
CD25  cells that accumulate to comprise  70% of the
CD4  T cells at the effector site during tumor progression
suppress the local immune response. We speculated that
poor immunogenicity of the cancer might be attributed to
immune regulation mechanisms by CD4 CD25  T cells ac-
cumulating in the tumor environment.
CD4 CD25  T cells suppress antitumor immunity
To examine whether tumor-infiltrating CD4 CD25  T cells
suppress T cell responses in vitro, we isolated the CD4  T
cells from the tumor tissues that had been established for 16 d
in C3B6F1 mice and coculture them with purified CD4 
CD25  T cells from naive C3B6F1 mice in the presence of an
optimal dose of plate-bound stimulatory anti-CD3 antibody.
We observed that these tumor-infiltrating CD4  T cells did
significantly suppress the proliferation of CD4 CD25  T cells
measured by 3H incorporation although the CD4  T cells iso-
lated from the spleen of tumor-bearing mice did not (Fig. 1 e).
Because CD4  and CD8  cells can express CD25 during the
early stage of T cell activation, it raises the concern that deple-
tion of CD25  cells in vivo would also eliminate the CD8  T
cells that are being activated. However, we observed that the
majority of CD8  T cells were CD25  in both spleen and
tumor at 2 wk after tumor challenge (Fig. 1 f). Depletion of
CD25  cells did not reduce the CD8  population because
only a relatively few CD8  cells express CD25 (Fig. 1 f). Ei-
ther CD4 CD25  cells preferentially accumulated or CD8 
cells failed to express CD25 inside tumor environment. To di-
rectly study the essential role of CD4  T cells in tumor im-
munity in vivo, we depleted CD4  cells and then observed
the tumor growth. Impressively, the highly vascularized and
poorly immunogenic Ag104Ld tumor was rejected rapidly in
all of the 22 mice when the CD4  cells were depleted (Fig. 1
g and Table II). Tumor rejection upon depletion of CD4 
cells was CD8  cell dependent because tumor grew uncon-
trollably in the absence of both CD4  and CD8  cells (Table
II). Depletion of NK1.1  NK and NKT cells did not cause
tumor rejection (Table II). To confirm that the subset of
CD4  T cells that express CD25 mainly contributes to the
suppression of antitumor immunity in vivo, we treated mice
bearing tumor for 2 wk with anti-CD25 antibody. Depletion
of CD25  cells with the antibody 14 d after tumor challenge
dramatically suppressed the tumor growth in all of the 12 mice
examined (Fig. 1 h). These data suggest that CD25  T cells
are mainly suppressive during the late phase of antitumor im-
mune responses.
Even in the absence of antigen Ld, depletion of CD4 
cells allowed 50% of the mice to reject the parental Ag104
tumor completely (Table II) and the remaining 50% of mice
had delayed tumor growth kinetics (unpublished data).
These observations suggest that other tumor antigens may
also induce antitumor immunity once CD4-mediated sup-
pression is removed. To test whether rejection leads to pro-
Table II. Augmented rejection of tumor through elimination of CD4  cells
Tumor challengea
Group Tumor line Dose Treatment
Incidence of tumor 
growthb Percent
1 Ag104Ld 106 None 33/33 100
21 0 5 27/27 100
31 0 6 CD4 depletionc 0/9 0
41 0 5 0/13 0
51 0 5 CD4 and CD8
depletiond
6/6 100
61 0 6 NK depletione 3/3 100
71 0 5 NK and NKT depletionf 6/6 100
8 Ag104 105 None 15/15 100
91 0 5 CD4 depletionc 4/8 50
aNumber of tumor cells as indicated were injected s.c. to C3B6F1 mice.
bThe results were pooled from independent experiments. p-values calculated by chi-square test between groups were shown as follows: P   0.001 for group 1 versus group 
3, group 2 versus group 4, and group 4 versus group 5, P   0.0015 for group 8 versus group 9. 
cCD4  cells were depleted by anti-CD4 antibody 3 d before and 10 d after tumor challenge.
dCD4  cells were depleted by anti-CD4 antibody 3 d before and 10 d after tumor challenge. CD8  cells were depleted by anti-CD8 antibody 14 d after tumor challenge.
eNK cells were depleted by antiasialo GM-1 antibody 3 d before tumor challenge.
fNK and NKT cells were depleted by anti-NK1.1 antibody 3 d before and 10 d after tumor challenge. Depletion of various cell populations was confirmed by checking peripheral 
blood by FACS.INTRATUMOR REGULATORY T CELLS SUPPRESS ANTITUMOR IMMUNITY | Yu et al. 784
tective immunity against other tumor antigens, Ag104Ld tu-
mor cells were initially inoculated and the CD4  cells were
depleted 14 d later. The rejection of tumor by depletion of
CD4  cells led to protection against future challenges not
only of Ag104Ld tumor cells but also of the parental Ag104
tumor cells (Table I). Our data suggest that the removal of
suppressive CD4  cells allows an expanded repertoire of
CD8  cells to participate in protective immunity.
Regulatory T cells suppress CD8  T cells at 
the effector phase
To test whether it is essential that CD4  cells suppressed
CD8  T cell responses at the priming phase leading to pro-
gressive tumor growth, we first depleted CD4  cells 3 d be-
fore tumor challenge. FACS analysis on the peripheral blood
confirmed that the treatment with titrated dose of anti-CD4
antibody only eliminated CD4  cells during the first 20 d of
tumor growth. Delayed, yet progressive tumor develop-
ment, observed in 11 out of 12 mice, resulted from CD4 de-
pletion 3 d before tumor challenge, thus depleting CD4  T
cells during the early, predominantly priming phase of the
antitumor response (Table III). However, we observed that
CD4 depletion throughout the entire duration of tumor
growth accomplished by injecting anti-CD4 antibody 3 d
before and 10 d after tumor challenge, led to complete tu-
mor rejection (Table III). This observation raised the possi-
bility that eliminating CD4 CD25  regulatory cells during
the effector phase was essential for rescuing CD8  T cell re-
sponses in the tumor. To test this hypothesis, tumor-bearing
mice were treated with anti-CD4 antibody 20 d after tumor
challenge when tumors were  1 cm in average diameter
(or  500 mm3 in average volume). Complete tumor regres-
sion was observed in 29/29 tumor-bearing mice (Table III).
We have yet to see any other immunoregulatory treatment
that can result in the complete destruction of such a massive,
well vascularized, highly progressive tumor. These data sug-
gest that the absence of suppressive CD4  T cells during the
late stage of immune responses can be essential and sufficient
to rescue antitumor immunity mediated by CD8  T cells,
which then causes tumor rejection.
As described above, CD4 depletion-mediated tumor re-
jection was dependent on CD8  T cells, suggesting that
CD4  cells might suppress CD8  cells inside the tumor. We
next examined how the CD4  cells suppress CD8  T cell
function. First, we detected a dramatic increase of CD8  T
cells inside the tumor after CD4  T cell depletion (Fig. 2 a)
and increased IFN-  production by the CD8  T cells (Fig. 2
b). It suggested that CD4  cells may inhibit the expansion of
CD8  cells responding to the tumor. To test this hypothesis,
we adoptively transferred CFSE-labeled effector 2C T cells,
activated in 2C/Rag-1 /  mice by MC57-SIY tumor cells
(50) into Ag104Ld-bearing C3B6F1 mice. 2C T cells were
derived from TCR transgenic 2C mice, that can directly rec-
ognize the Ld antigen on Ag104Ld. These transferred effector
2C T cells expressed high levels of CD44 and down-regu-
lated CD62L expression. However, adoptive transfer of 3  
106 of these activated effector 2C T cells was not sufficient to
cause tumor rejection (unpublished data). Before CD4  T
cell depletion, only a few CFSE-labeled effector 2C T cells
were present inside the tumor, but after depletion, a dramatic
increase in number and percentage of the effector cells was
observed (Fig. 2 c). More importantly, proliferation of these
2C T cells occurred mainly at the effector site upon depletion
of CD4  T cells, suggesting that suppression predominantly
occurs at the local tumor site (Fig. 2 c). Therefore, these
CD4  cells suppressed proliferation, maturation, and expan-
sion of CD8  T cells at the tumor site.
IL-10 and TGF-  are involved in the suppression 
mechanisms in vivo
To explore the mechanisms of how CD4  cells suppressed
antitumor immunity, we compared the levels of cytokines in
the spleen and tumor before and after CD4  cell depletion.
In the spleen, there were no significant differences in the lev-
els of cytokines that were detected in the presence or absence
of CD4  cells (Fig. 3 a). The Th2 cytokines, IL-4 and IL-5,
did not show significant difference at the tumor site in the
presence or absence of CD4  T cells (Fig. 3 b). However, in
the absence of CD4  T cells, inflammatory cytokines includ-
ing IFN- , TNF, IL-6, and MCP-1 were increased dramati-
Table III. Suppression by CD4  cells is in effector phase rather than priming phase
Tumor challengea
Group Tumor line Dose
Anti-CD4 treatment
day relative to tumor challenge [0]b
Incidence of tumor 
growthc Percent
1 Ag104Ld 105  3 and 10 0/13 0
2  3 11/12 92
3 20 0/21 0
45     105 20d 0/8 0
aNumber of tumor cells as indicated were injected s.c. to C3B6F1 mice.
bAssume that tumor challenge is on day 0. CD4  cells were depleted by anti-CD4 antibody. Days on which CD4  cells were absent were confirmed by checking peripheral blood 
by FACS.
cThe results were pooled from multiple independent experiments. p-values calculated by chi-square test between groups were shown as follows: P   0.001 for group 1 versus 
group 2 and group 2 versus group 3.
dThe average tumor size reached  500 mm3.JEM VOL. 201, March 7, 2005 785
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cally in the tumor tissues compared with the levels in the
presence of CD4  cells. The level of the antiinflammatory
cytokine IL-10 was also much lower after the depletion of
CD4  cells (Fig. 3 b). These results suggested that the CD4 
cells maintained an antiinflammatory environment that in-
hibited antitumor immunity inside the tumor.
We hypothesized that antitumor immunity could be pro-
moted if we blocked the effects of the antiinflammatory cy-
tokines. Indeed, tumor growth was dramatically inhibited in
all of the 11 mice after the treatment with anti–IL-10 recep-
tor (IL-10R) antibody (Fig. 3 c). The tumor growth was fur-
ther inhibited in all of the 16 mice after the treatment with
anti–IL-10R antibody in combination with inflammatory
signals, such as LPS or agonistic anti-CD40 antibody (Fig. 3 c).
Administration of LPS alone did not change tumor growth
significantly, suggesting activation of DCs through toll-like
receptor 4 (TLR4) alone may not be sufficient to reverse sup-
pression (unpublished data). TGF-  is another cytokine that
can suppress inflammatory responses. To investigate the role
of TGF-  in this model, we blocked TGF-  at the time of
challenge with Ag104Ld tumor cells. The tumors were com-
pletely rejected in all of the 6 mice after the blockade of
TGF- , whereas all of the 27 mice with control treatment
died of tumor burden (P   0.001, Chi-square test). The rep-
resentative pattern of the tumor growth in one of the experi-
ments was shown (Fig. 3 d). These results showed that the
antiinflammatory environment inside the tumor correlates
with the failure of tumor rejection. The CD4  cells appear to
actively maintain this antiinflammatory environment inside
the tumor to suppress the antitumor immune response,
thereby promoting the growth of the antigenic tumors.
Depletion of CD4 CD25  T cells at the effector site 
eradicates established tumors
Considering CD4 CD25  T cells are the main population
of CD4  T cells inside tumor during its progression, we
propose that depletion of CD4  cells at the tumor sites is
sufficient to achieve tumor rejection. Selective depletion of
CD4  cells in the tumor-bearing hosts at the tumor site us-
ing a small amount of anti-CD4 antibody may efficiently
reverse immune tolerance of CD8  cells to the tumor while
retaining normal numbers of CD4  cells in the lymphoid tis-
Figure 2. CD4  cells suppress the proliferation and IFN-  produc-
tion of tumor-infiltrating CD8  T cells. 106 Ag104Ld tumor cells were 
inoculated to C3B6F1 mice s.c. and anti-CD4 antibody (GK1.5) was in-
jected i.p. 14 d after tumor challenge. Spleen as well as tumor tissue were 
isolated from mice 1 wk after CD4 depletion. The percentage of CD8  T cells 
in the tumor tissue was determined by FACS (a). The tumor-infiltrating T
cells (TIL) were enriched with anti-Thy1.2 magnetic bead system. Spleen 
cells and purified TIL were stimulated in vitro with PMA and ionomycin in 
the presence of brefeldin A for 4 h. The percentage of IFN- –producing 
CD8  T cells among total CD8  T cells in the tumor was determined by 
FACS (b). 106 MC57-SIY tumor cells were injected at multiple sites s.c. to 
2C TCR transgenic mice in Rag-1 /  background to activate 2C T cells. 2C 
T cells were isolated 96 h after activation and of CD62LloCD44high pheno-
type. CFSE-labeled activated 2C T cells were adoptively transferred to 
these Ag104Ld tumor bearing mice with or without CD4 depletion. Tumor 
tissue was collected from mice 2 d after transfer of 2C T cell. The prolifer-
ation of CFSE-labeled 2C T cells was monitored by FACS (c). Results from 
one experiment representative of three were shown.INTRATUMOR REGULATORY T CELLS SUPPRESS ANTITUMOR IMMUNITY | Yu et al. 786
Figure 3. CD4  cells maintain an antiinflammatory environment 
inside the tumor. (a and b) CD4  cells were depleted by treating the 
mice with anti-CD4 antibody i.p.1 d before tumor challenge. 106 Ag104Ld 
tumor cells were inoculated to C3B6F1 mice s.c. and spleen (a) as well as 
tumor tissue (b) were collected from mice 2 wk after tumor challenge and 
homogenized. The debris was spun down and the supernatant was col-
lected and subjected to CBA kit. Seven mice from CD4-depleted or control 
group were used. Data shown were means and SD. (c) 105 Ag104Ld tumor 
cells were inoculated to C3B6F1 mice s.c. and 100  g of blocking anti–IL-10 
receptor (IL-10R) antibody was injected to mice 1 d before and 7 d after 
tumor challenge. In combination with anti–IL-10R treatment, 100  g of 
LPS or 100  g of agonistic anti-CD40 antibody was given to mice i.p. 7 d 
after tumor challenge. Tumor growth was monitored. Data shown were 
means of tumor volume from 8 to 11 mice in each group and SD. The dif-
ference in tumor growth between the control group and all of the treated 
groups, as well as the anti–IL-10R–treated group with the ones in combi-
nation with LPS or anti-CD40 was significant by statistical analysis with 
the random effect models for longitudinal data (P   0.001). Statistical 
analysis with t test also showed that the difference in tumor size be-
tween the control group and all of the treated groups was significant JEM VOL. 201, March 7, 2005 787
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sues. To ensure that the depletion of CD4 -suppressive cells
at the effector site after tumor’s establishment can promote
antitumor immunity, we used low doses of anti-CD4 anti-
body (12.5–50  g/injection) for intratumor injection to as-
sure depletion of CD4  T cells inside the tumor but not sys-
temically (Fig. 4 a). We found that intratumor depletion of
CD4  cells 14 d after tumor inoculation rapidly caused the
complete rejection of well-established tumors in all of the 21
mice that were treated (Fig. 4 b). This result confirms that
depletion of CD4 -suppressive cells inside the tumor is suf-
ficient to cause the rejection of an established tumor and
suggests that the active suppression of antitumor CD8  T
cells mainly occurs at the effector site and that it is reversible.
Importantly, local treatment can become an affordable and
effective treatment for tumor immunotherapy.
DISCUSSION
Poor immune responses to weak tumor antigens is often be-
lieved to be the basis for the progressive growth of tumors in
immunocompetent hosts, and is assumed to be a major hurdle
for successful immunotherapy. In our study, we introduced
a strong Ld alloantigen into the murine Ag104 fibrosarcoma
cell line, a highly progressive, invasive, and vascularizing
tumor that can kill the host in a few weeks. However, the
presence of a strong antigen could not elicit an antitumor im-
mune response that prevented or retarded the growth of the
tumor. Although infiltration of lymphocytes is commonly
observed in both human and animal cancers (19–22), im-
mune rejection of cancer is rarely observed. In spite of obvi-
ous T cell infiltration, the failure of the host to eradicate the
tumor is a confounding phenomenon that has not been well
understood. A closer examination of TIL in our animal
model revealed that the CD4  subset, CD4 CD25  T cells,
selectively accumulate inside the tumor and comprise the
majority of the total TIL. We further show that, during tu-
mor progression, CD4 CD25  T cells primarily mediate a
suppressive environment inside the tumor and abrogate the
effector function of CD8  T cells. Local intratumoral deple-
tion of these regulatory T cells unmasks the immunogenicity
of the tumor and reverse CTL tolerization leading to the
rapid rejection of well-established tumors. More importantly,
in this study we demonstrated that T regulatory cells can be
one important local factor to suppress immune responses
against a strong tumor antigen leading to progressive growth
of cancer in the immune-competent hosts.
The role of CD4  T cells in tumor immunity has been
extensively studied (51). CD4  T cells have been shown to
play an essential role in promoting CD8  T cell responses
(52–54) and the development of CD8 T cell memory (55–
57). In antitumor immunity, CD4  T cells also have been
demonstrated to be important in sustaining the functions of
adoptively transferred CD8  T cells (50, 58, 59). Depletion
of CD4  cells in mice significantly diminished the ability of
GM-CSF vaccine/anti-CTLA4 treatment to protect the ani-
mals from subsequent tumor challenge (60). On the other
hand, early studies by Robert North have shown that intra-
venous injection of a depleting anti-CD4 antibody at early
stages of tumor growth led to CD8  T cell–mediated tumor
after 14 d after tumor inoculation (P   0.001, t test). The difference in 
tumor size between group treated with anti–IL-10R antibody and the 
ones treated in combination with LPS or anti-CD40 groups was signifi-
cant after 18 d after tumor inoculation (P   0.001, t test). (d) 105 
Ag104Ld tumor cells were inoculated to C3B6F1 mice s.c. and anti-CD4 
antibody or 250  g anti-TGF-  antibody was injected to mice 1 d before 
and 7 d after tumor challenge. The representative pattern of tumor 
growth in one experiment was shown.
Figure 4. Intratumor depletion of CD4  cells leads to rejection of 
established tumor. 105 Ag104Ld tumor cells were inoculated to C3B6F1 
mice s.c. and 12.5–50  g anti-CD4 antibody (GK1.5) was injected intratu-
morally, once every 7 d, starting 14 d after tumor challenge. The arrow 
indicated the first treatment. Spleen as well as tumor tissue were isolated 
from mice 2 d after CD4 depletion. The percentage of CD4  T cells in the 
spleen or tumor tissue was determined by FACS (a). Tumor growth was 
monitored and data shown was representative pattern of tumor growth in 
one of five experiments comprising 21 mice (b).INTRATUMOR REGULATORY T CELLS SUPPRESS ANTITUMOR IMMUNITY | Yu et al. 788
regression (36–38). Recent studies strongly support the no-
tion that a population of CD4  cells, CD4 CD25  T cells,
significantly limits the efficacy of vaccine-induced antitumor
immune responses, and their inhibition or elimination be-
fore tumor challenge could significantly enhance antitumor
immunity(39–42, 61–66). For example, in a study, a combi-
nation of a GM-CSF–transduced tumor vaccine plus anti-
CTLA4 was more effective at eliminating established tumors
when animals were treated with anti-CD25 antibodies be-
fore tumor challenge (39). Another study revealed that
splenic cells depleted of CD4 CD25  T cells can mediate
tumor regression presumably through promoting autoreac-
tivity because autoimmune diseases were also induced (41).
Although these studies suggest that regulatory T cells may
inhibit initial priming of CD8  T cells, some of which rec-
ognize self antigens, our data strongly demonstrate that
CD4 CD25  T cells selectively accumulate inside the tu-
mor and play a greater role in suppressing the CD8  T cell
function at the effector phase of tumor progression and
maintaining the local immune tolerance permissive of pro-
gressive growth of an antigenic tumor.
It has been a general concern that the depletion of
CD4 CD25  T cells in the tumor-bearing hosts may unwit-
tingly eliminate the helper function of CD4  T cells, which
can also express the CD25  marker after activation by tumor
or by vaccination. We propose that CD4  cells predomi-
nately play an enhancing helper role during the initial stages,
but once tumors become chronically persistent and estab-
lished, the increased accumulation of CD4  regulatory T
cells inhibit CD8  cell function and mask the immunoge-
nicity of tumor. Our study indeed establishes that the sup-
pression of immunity against tumor by CD4 CD25  T
cells, chiefly CD8  T cell responses, mainly occurs in the ef-
fector phase at tumor site and that depletion of the regula-
tory T cells at the late stage of tumor progression does not
mitigate the possible T helper function. In fact, depletion of
regulatory T cells unveils the immunogenicity of tumor cells
and provides long-term protection against rechallenge of
even the parental tumor cells lacking the strong antigen Ld.
This result suggests that the induction of immunity was not
exclusively against Ld, but rather, the depletion of regulatory
T cells promoted immunity against previously poorly immu-
nogenic tumor antigens and expanded the tumor-reactive
CD8  T cell repertoire. The parental Ag104 (without Ld), a
highly progressive and poorly immunogenic tumor, fails to
respond to various conventional immunotherapies but shows
increased immunogenicity leading to tumor rejection or de-
layed tumor progression after depletion of regulatory T cells.
It is conceivable that this strong antitumor immunity in-
duced locally by depletion of CD4  cells may also lead to
the rejection of tumors at distal sites.
It has been shown that CD4 CD25  T cell subset plays
critical roles in down-regulating autoimmune inflammation
and concomitant immunity during persistent infection (31–
35). Tumor microenvironment may allow the activation or
expansion of regulatory T cells after the progression of
tumors. We speculate that chronic inflammation inside the
tumor tissue may resemble some aspects of protective im-
munity to normal tissues during chronic autoimmune inflam-
mation or persistent infection, which allows the accumula-
tion of the CD4 CD25  T cell subset to down-regulate
immune responses, limit local inflammation, and reduce local
tissue destruction. In addition, tumor-mediated suppressive
factors may favor the survival of regulatory T cells over effec-
tor T cells. As a consequence, it is possible that the same reg-
ulatory mechanisms designed to prevent uncontrolled inflam-
matory responses in normal tissues are turned on to inhibit
antitumor immunity. It is not uncommon to find that tumor-
infiltrating T cells, which contain the CD4 CD25  popula-
tion, in various tumor tissues (22, 67–71). Our study revealed
that the population of tumor-infiltrating cells is skewed to fa-
vor regulatory CD4  T cells over the helper CD4  T cells
within the tumor tissue, especially as tumor progresses and
gets established in the host. Therefore, understanding the na-
ture of tumor-infiltrating CD4  T cells by surface markers or
cytokine profiles would not only avoid possible deleterious
effects of regulatory CD4  T cells in an adoptive transfer im-
munotherapy, but would also allow informed predictions
about the prognosis of cancer patients.
Understanding the balance of T effector versus T regula-
tory cells may be more important to determine the outcome
of immune responses inside tumors. Our recent study has
demonstrated that rapid recruitment of naive lymphocytes
and expansion of CD8  T cells inside the tumor may be a
way of creating a dominant proinflammatory environment,
leading to the rejection of tumor at local and distal sites (72).
Now, we have further demonstrated in this study that the
depletion of regulatory T cells is another efficient way of
converting the antiinflammatory environment inside tumor
to proinflammatory one. The local treatment to eliminate
regulatory T cells has certain critical advantages over sys-
temic treatment. First, local treatment may avoid side effects
induced by systemic depletion of all CD4  T cells, which
may abrogate T helper–mediated protective immunity
against pathogens. Second, it would not hinder effective
priming of CD8  T cell in the lymphoid tissues by the
helper CD4  T cells, because depletion remains local. Third,
the local treatment would be even expected to be more ef-
fective because the key suppression of CD4 CD25  regula-
tory T cells resides inside tumor. Also intratumoral treatment
would reduce the dose of antibody to be applied to the pa-
tients as well as be more affordable even for the developing
countries. CD4 CD25  T cells have been shown to be
present in a variety of human cancer tissues (22, 67–71). A
study published recently revealed that CD4 CD25  T cells
are negatively associated with the prognosis of the ovarian
cancer patients (22). Therefore, regulatory T cells within the
tumor environment represent an attractive target, and their
depletion may lead to improvements in the current immu-
notherapy protocol in the future clinical trials. It is likely thatJEM VOL. 201, March 7, 2005 789
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a combination treatment, which would rapidly expand the
effector cells at the tumor site while locally depleting the
regulatory cells, could potentially provide a potent strategy
for enhancing antitumor immunity and permitting a clini-
cally desirable outcome for cancer patients.
MATERIALS AND METHODS
Mice and cell lines.  Female C3B6F1 and C3H mice, aged 5–8 wk,
were purchased from the Frederick Cancer Research Facility of the US Na-
tional Cancer Institute (Frederick, MD) and were maintained in a specific
pathogen-free facility at the University of Chicago (Chicago, IL). Animal
care and experiments were done in accordance with institutional and Na-
tional Institutes of Health (NIH) guidelines and were approved by an ani-
mal use committee at the University of Chicago. The Ag104 fibrosarcoma
and Ag104 cell line (43) expressing murine H-2Ld (Ag104-Ld) has been de-
scribed previously (1).
Measurement of cytokines in the spleen and tumor. We prepared
tumor and spleen homogenates as described previously (72). In brief, com-
parable amounts of tumor or spleen tissues were collected, weighed, and
homogenized in PBS containing protease inhibitors, and the supernatants
were collected by centrifugation. The amount of cytokines in the superna-
tants was quantified using the cytometric bead array kit (CBA; BD Bio-
sciences) on a FACSCaliber cytometer equipped with CellQuestPro and
CBA software (Becton Dickinson) according to manufacture’s instructions.
Flow cytometric analysis. FACS analyses were performed using FITC-,
PE-, Cy-chrome– or biotin-conjugated antibodies to mouse CD45RB, CD4,
CD8, CD25, and IFN  (all BD Biosciences). Streptavidin–Cy-chrome
conjugate was from BD Biosciences; biotin-conjugated clonotypic antibody
(1B2) to 2C TCR and cell staining was performed as described previously
(50). For intracellular cytokine staining, T cells purified from the tumor tis-
sue were restimulated for 4 h with PMA (50 ng/ml; Sigma-Aldrich) and
ionomycin (500 ng/ml; Sigma-Aldrich) in the presence of brefeldin A
(Sigma-Aldrich). For analysis of CFSE-labeled 2C T cells, isolated tumor or
spleen single-cell suspensions were stained with biotinylated 1B2 antibody,
washed, and stained with a mixture of PE-coupled anti-CD8 and Cy-
chrome–coupled streptavidin. FACS data were analyzed with FlowJo soft-
ware (Becton Dickinson)
Cell isolation and in vitro assay.  To isolate CD4  T cells from the tu-
mor tissue, the mice were first bled to decrease the contamination of tumor
tissue by blood. Tumor tissues were collected, washed in PBS, cut into
pieces and resuspended in Dulbecco’s modified Eagle’s medium supple-
mented with 2% fetal calf serum and 1.5 mg/ml of collagenase D (collage-
nase D solution) for 25 min in a 37 C shaking incubator. The cell suspen-
sion was collected after 25 min, and the cell clumps were digested for
another 25 min in collagenase D solution until all of the tumor tissue had
resolved into a single-cell suspension. Tumor-infiltrating T cells were en-
riched from this single-cell suspension with biotin-conjugated Thy-1.2 an-
tibody followed by antibiotin magnetic beads using the AutoMACS system
(Miltenyi Biotech). Enriched tumor-infiltrating T cells were stained with
PE-conjugated anti-CD4 and FACS-sorted into CD4  population on a
MoFlo. CD4  or CD4 CD25  and CD4 CD25  cells were purified from
splenic single-cell suspensions with CD4  T cells or CD4 CD25  regula-
tory T cell isolation magnetic bead system (Miltenyi Biotech), respectively,
using the AutoMACS system (Miltenyi Biotech). For all the cell isolations,
 90% purity of desired population was routinely obtained. For T cell co-
stimulation assay, we coated 96-well plates with 50  l of 2  g/ml anti-CD3
antibody overnight. The plates were then washed with PBS and 6   104
purified CD4 CD25  T cells were cultured per well with or without 6  
104 isolated CD4  T cells from the spleen or tumor tissue of the tumor
bearing mice. In all assays, T cell proliferation was measured by adding 1
 Ci of [3H]thymidine per well for the last 24 h of the 3-d culture.
[3H]Thymidine incorporation was measured in a TopCount microplate
scintillation counter (Packard Instrument Co.).
Adoptive transfer of 2C T cells. We first activated 2C T cells by inocu-
lation of 106 MC57-SIY tumor cells s.c. at multiple sites to 2C mice in B6/
Rag-1 /  background (2C mice; 50). We then isolated lymph node cells
and splenocytes from these challenged 2C mice and negatively selected for
CD8  T cells with a CD8  T cell enrichment kit (Miltenyi Biotec) 5 d af-
ter tumor cell inoculation. When analyzed, majority of the 2C cells ex-
pressed CD44high CD62Llow phenotype. These 2C T cells were then labeled
with CFSE as described previously (50). We injected 3   106 CFSE-labeled
T cells in a 0.2-ml volume intravenously into the retro-orbital plexus of the
tumor-bearing mice. Cells were isolated from the spleen and tumors 48 h
after transfer and subjected to FACS analysis.
Cell depletions and cytokine blockade in vivo.  Mice were depleted
of lymphocyte subsets systemically by standard procedures (50), using mAb
GK1.5 for CD4  cells, mAb 2.34 for CD8  cells and PC61 for CD25 
cells. Examination of splenocytes and lymph node cells by flow cytometry
showed that the depleted CD4  or CD8  subset represented  0.5% of the
total lymphocytes, with normal levels of other subsets. Intratumor CD4 
cell depletion was done using 12.5 to 50  g GK1.5 in 50  l PBS. To block
IL-10 or TGF- , 100  g anti–IL-10 receptor or 250  g anti-TGF-  anti-
bodies (A411) were injected to the mice i.p. 1 d before and 7 d after tumor
challenge. 100  g LPS or agonistic anti-CD40 antibody was given to the
mice i.p. 7 d after tumor challenge.
Real-time quantitative RT-PCR assay.  The real-time quantitative
RT-PCR assay for foxp3 was done as described previously (73). In brief, to-
tal RNA from tumors was isolated, and 5  g of total RNA was reverse tran-
scribed into cDNA by using the First Strand cDNA Synthesis Kit (Amer-
sham Biosciences). Real-time quantitative PCR analysis was done on a
SmartCycler real-time thermal cycler (Cepheid). Each cDNA sample was
amplified for foxp3 and GAPDH by using the TaqMan universal PCR mas-
ter mixture containing AmpliTaq gold DNA polymerase in accordance with
the manufacturer’s instructions (PerkinElmer). We determined the concen-
tration of target gene by the comparative CT (threshold cycle number at the
cross-point between amplification plot and threshold) method and normal-
ized values to the internal GAPDH control. The primer sequences for foxp3
were 5 -CCCAGGAAAGACAGCAACCTT-3  (forward primer) and 5 -
TTCTCACAACCAGGCCACTTG-3  (reverse primer), and the probe for
foxp3 was 5 -ATCCTACCCACTGCTGGCAAATGGAGTC-3 .
Statistical analysis for difference in tumor growth. Because the tu-
mor growth was observed repeatedly over time on the same mouse, the ran-
dom effect models for longitudinal data were used to analyze such data. For
each experiment, the tumor growth was assumed to depend on treatment and
to follow a linear growth rate over time. The model gave an overall estimate
of the intercept and slope of the linear growth for each group. Both the inter-
cept and slope were allowed to vary among individual mouse. We were inter-
ested mainly in comparing whether the slope, i.e., the growth rate, was differ-
ent among different treatment groups. Because the actual tumor growth may
not follow a linear growth trend over the entire follow up period. The in-
crease of tumor growth was slow at the early stage and became rapid at the
later stage in some experiments. We also investigated this by adding a qua-
dratic term of the follow-up time in the above random effect models.
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